Deborah K Armstrong

No ORCID on file · 4 papers in corpus
rct 2019
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
The New England journal of medicine ·doi:10.1056/nejmoa1902626

BACKGROUND: Secondary surgical cytoreduction in women with platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian-tube ("ovarian") cancer is widely practiced but has not been evaluated in phase 3 investigation. …

other 2017
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience
Gynecologic Oncology ·doi:10.1016/j.ygyno.2017.08.004

PURPOSE: We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). METHODS: We reviewed data from FIGO stage I-IV epithelial ovarian cancer patients who parti…

review 2011
Recent progress in the diagnosis and treatment of ovarian cancer
CA: a cancer journal for clinicians ·doi:10.3322/caac.20113

Epithelial ovarian cancer is the most lethal of the gynecologic malignancies, largely due to the advanced stage at diagnosis in most patients. Screening strategies using ultrasound and the cancer antigen (CA) 125 tumor marker are currently …

rct 2009
A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172
Gynecologic Oncology ·doi:10.1016/j.ygyno.2009.06.021

OBJECTIVE: Serum CA-125 values have been advocated in the monitoring of ovarian cancer patients receiving intravenous (IV) chemotherapy. This evaluation sought to determine if the CA-125 test can be used to monitor treatment effect among pa…